Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

Levi, Raphael; Aboud-Pirak, Esther; Leclerc, C.; Lowell, George H.; Arnon, Ruth

doi:10.1016/0264-410x(94)00083-y

Cited by 56 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The elevated titer of lungs IgA specific to the peptide and to the intact virus is indicative of a successful induction of local immunity. 38,39 In later studies, additional epitopes were included in the vaccine in an effort to improve the level of protection that had been achieved by immunization with the single B cell epitope HA 91-108. For this purpose, two T cell epitopes were examined: the T helper epitope (NP 55-69) 40 and a CTL epitope (NP 147-158).…”

Section: Epitope-based Vaccinesmentioning

confidence: 99%

Towards an Epitope-Based Human Vaccine for Influenza

Ben-Yedidia

Arnon

2005

Human Vaccines

Self Cite

View full text Add to dashboard Cite

Section: Epitope-based Vaccinesmentioning

confidence: 99%

Towards an Epitope-Based Human Vaccine for Influenza

Ben-Yedidia

Arnon

2005

Human Vaccines

Self Cite

View full text Add to dashboard Cite

“…There are many conservative segments on HA (data not shown), but to be a target of humoral immune response, they should be on the surface of the protein. The B cell epitope property of the F3 region has been demonstrated [21, 24]. These results indicate that F3 can be a good immune target.…”

Section: Resultsmentioning

confidence: 75%

“…Many synthetic vaccines have been studied to increase the neutralizing capacity. But the main trend is to develop a better carrier component or more efficient adjuvant [21, 22, 26, 27]. Here, we suggested that an epitope vaccine may be a new strategy against influenza.…”

Section: Discussionmentioning

confidence: 99%

“…Peptide HA1 (183–199), which was conjugated to tetanus toxid, can induce both humoral and T cell responses and protect Balb/c mice from lethal viral infection [20]. And another three peptides containing three different epitopes (B, T and CTL epitope) on HA (91–108, 55–69 and 147–158), which were anchored to proteosome vesicles prepared from meningococci, can also elicit humoral and cellular specific immune responses and lead to partial protection of the mice from viral challenge [21]. Among these three peptides, peptide 91–108 itself could also induce neutralizing activity in mice [22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Candidate Vaccine against Influenza Virus Intensively Improved the Immunogenicity of a Neutralizing Epitope

Ding²,

Liu³

et al. 2002

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The hemagglutinin (HA) of influenza viruses is one of the major targets of the humoral response. The role of serum antibody to HA in the protection against infection has been demonstrated by long-standing observation. In previous studies, we suggested that an epitope vaccine might be a new strategy against the virus. Methods: HA sequences of 491 H3 subtype strains from the influenza sequence database were compared and analyzed. To acquire information on the immunogenicity of the F3 epitope, F3-epitope-specific antibody levels in 81 patient sera infected with influenza virus were tested by ELISA. Based on the theory of the epitope vaccine, we designed an epitope peptide F3 (C-KAYSNCYPYDVPDY-G-KAYSNCYPYDVPDY), which contains the repeated F3 epitope KAYSNCYPYDVPDY (aa92–105) on HA (H3N2). The specificity and the titer of the antibodies induced by the epitope vaccine were determined by ELISA. The neutralizing activities of these anti-F3 antibodies were shown by inhibiting influenza virus infection of MDCK cells. Results and Conclusion: Comparison of HA sequences of 491 H3 subtype strains indicates that this epitope is highly conservative. Analysis of the sera from influenza virus-infected patients revealed a very low level of F3 epitope-specific antibodies, suggesting the poor immunogenicity of the F3 epitope on influenza virus. The epitope vaccine based on the F3 epitope induced high levels of F3 epitope-specific antibodies recognizing the epitope peptide F3 (antibody titer in antisera up to 1:25,600). Besides, the antisera could also recognize the natural HA in Western blotting. Interestingly, these antisera induced by the epitope vaccine could inhibit infection of MDCK cells by influenza virus (strain A/Wuhan/359/95) in the neutralization assay. These results suggest that the epitope vaccine can intensively increase the immunogenicity of neutralizing epitopes and may provide a new way to develop an effective vaccine against influenza virus.

show abstract

“…In previous studies, a synthetic peptide matching this sequence and conjugated to tetanus toxoid elicited neutra lizing antibodies and partial protection of mice against viral challenge [22,23], The second epitope encompasses the re gion 55-69 of the highly conserved NP, which was reported to be a T helper epitope [24], The third corresponds to the sequence 147-158 of the NP, which was shown to be a CTL epitope [25][26][27], and stimulated CTLs when coupled to a lipoprotein carrier [28], The peptides representing these three epitopes were prepared by chemical synthesis and used for immunization of rabbits and mice. Indeed, the HA 91-108 epitope led to efficient antibody production of both the IgG and the IgA classes, but did not induce cellular im munity, whereas the two NP epitopes induced an efficient cell-mediated response, as manifested by antigen-specific cell proliferation [29]. Furthermore, the synthetic peptide NP 147-155. which is the determining part of the 147-158 epitope, effected specific lysis of target cells by influenzavirus-stimulated CTLs [30].…”

Section: The Influenza Systemmentioning

confidence: 99%

Synthetic Recombinant Vaccines against Viral Agents

Arnon¹,

Levi²

1995

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Synthetic recombinant vaccines are expression vectors incorporating defined epitope(s) of microbial agents. They are prepared by inserting synthetic oligonucleotide(s) coding for previously identified relevant epitopes into the genome of a desired vector, using recombinant DNA technology. The results discussed indicate that immunization with such vaccines carrying viral epitopes may lead to protective immunity against viral agents. Oligonucleotides coding for three influenza epitopes stimulating B cells, T helper cells and cytotoxic lymphocytes were individually inserted into the flagellin gene of a Salmonella vaccine strain. Immunization of mice with the resultant recombinant bacteria or their isolated flagella induced a specific mucosal anti-influenza protective response. The most efficient vaccine consisted of all three recombinant flagella, administered intranasally. The protection elicited was cross-strain specific, long-lasting and efficient against a lethal viral challenge.

show abstract

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

Cited by 56 publications

References 33 publications

Towards an Epitope-Based Human Vaccine for Influenza

Towards an Epitope-Based Human Vaccine for Influenza

A Candidate Vaccine against Influenza Virus Intensively Improved the Immunogenicity of a Neutralizing Epitope

Synthetic Recombinant Vaccines against Viral Agents

Contact Info

Product

Resources

About